{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T04:15:05Z","timestamp":1747282505345,"version":"3.40.5"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2024,12,20]],"date-time":"2024-12-20T00:00:00Z","timestamp":1734652800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,5]]},"abstract":"<jats:sec>\n            <jats:title>Background and aims:<\/jats:title>\n            <jats:p>The aim of this study was to assess the health-related quality of life (HRQL) of children with chronic hepatitis C (CHC) at 1 year after the effective treatment with sofosbuvir\/velpatasvir (SOF\/VEL).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>All 50 patients treated for CHC with a fixed dose SOF\/VEL in the noncommercial, nonrandomized, open-label PANDAA-PED study achieved sustained virologic response at 12 weeks after the end of treatment. Evaluation of HRQL at 1-year posttreatment was compared with the baseline (before the treatment) assessment. KIDSCREEN-27 questionnaires, which included 5 dimensions of HRQL, for child self-reporting and parent proxy reporting were used. The normal range for the population was set to T values of 40\u201360 points. Child\u2013parent agreement was analyzed using the intraclass correlation coefficient (ICC).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Mean T values were within the normal range for all HRQL dimensions. A significant improvement in \u201cautonomy &amp; parent relation\u201d in children\u2019s self-assessment (from 48.3 to 51.5, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.03) was observed. In parent proxy assessment, a significant decrease occurred in \u201cschool\u201d dimension (from 49.5 to 45.8, <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.03), which was not revealed at 3-month posttreatment. Older age was associated with worse HRQL scores in all dimensions. Evaluation of the ICC for child self-reports versus parent proxy reports revealed poor-to-moderate agreement for most single measures, lower than at 3-month posttreatment analysis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>This is the first study to present the long-term influence of treatment with direct-acting antivirals on patient-reported outcomes in children. At 1 year after effective treatment with SOF\/VEL, an improvement in some areas of children\u2019s well-being was revealed, which may indicate also some patient-reported outcomes benefits of direct-acting antiviral therapy. Despite the improvement in the child self-report of \u201cautonomy &amp; parent relation,\u201d there was a more pronounced discrepancy between children self-reports and parents proxy reports in all dimensions of HRQL. Older patients\u2019 age correlated with worse HRQL assessment. If this finding is mediated by the duration of hepatitis C virus infection, it would support recommendation for the treatment of younger children.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004675","type":"journal-article","created":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T21:00:19Z","timestamp":1736283619000},"page":"405-410","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Health-related Quality of Life in Children and Adolescents After Successful Treatment of Chronic Hepatitis C With Sofosbuvir\/Velpatasvir: One-year Outcomes"],"prefix":"10.1097","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7783-6904","authenticated-orcid":false,"given":"Maria","family":"Pokorska-\u015apiewak","sequence":"first","affiliation":[{"name":"Department of Children\u2019s Infectious Diseases, Medical University of Warsaw, Warsaw, Poland"},{"name":"Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases in Warsaw, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1731-2329","authenticated-orcid":false,"given":"Anna","family":"Dobrzeniecka","sequence":"additional","affiliation":[{"name":"Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases in Warsaw, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3466-0782","authenticated-orcid":false,"given":"Ewa","family":"Talarek","sequence":"additional","affiliation":[{"name":"Department of Children\u2019s Infectious Diseases, Medical University of Warsaw, Warsaw, Poland"},{"name":"Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases in Warsaw, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Aniszewska","sequence":"additional","affiliation":[{"name":"Department of Children\u2019s Infectious Diseases, Medical University of Warsaw, Warsaw, Poland"},{"name":"Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases in Warsaw, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Pluta","sequence":"additional","affiliation":[{"name":"Department of Children\u2019s Infectious Diseases, Medical University of Warsaw, Warsaw, Poland"},{"name":"Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases in Warsaw, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Marczy\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Children\u2019s Infectious Diseases, Medical University of Warsaw, Warsaw, Poland"},{"name":"Department of Pediatric Infectious Diseases, Regional Hospital of Infectious Diseases in Warsaw, Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Indolfi","sequence":"additional","affiliation":[{"name":"Department of Neurofarba, Meyer Children\u2019s University of Florence, Florence, Italy"},{"name":"Meyer Children\u2019s Hospital IRCCS, Florence, Italy."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2024,12,20]]},"reference":[{"key":"R1-20250514","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/jvh.13005","article-title":"The comprehensive outcomes of hepatitis C virus infection: a multi-faceted chronic disease.","volume":"25","author":"Younossi","year":"2018","journal-title":"J Viral Hepat"},{"key":"R2-20250514","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.cgh.2019.07.047","article-title":"Long-term benefits of sustained virologic response for patient-reported outcomes in patients with chronic hepatitis C virus infection.","volume":"18","author":"Younossi","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R3-20250514","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/jpn3.12160","article-title":"ESPGHAN recommendations on treatment of chronic hepatitis C virus infection in adolescents and children including those living in resource-limited settings.","volume":"78","author":"Indolfi","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R4-20250514","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/liv.15827","article-title":"Efficacy and safety of DAA in children and adolescents with chronic HCV infection: a systematic review and meta-analysis.","volume":"44","author":"Indolfi","year":"2024","journal-title":"Liver Int"},{"key":"R5-20250514","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1111\/jvh.12830","article-title":"Quality of life in adolescents with hepatitis C treated with sofosbuvir and ribavirin.","volume":"25","author":"Younossi","year":"2018","journal-title":"J Viral Hepat"},{"key":"R6-20250514","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1097\/MPG.0000000000001754","article-title":"Health-related quality of life in adolescent patients with hepatitis C genotype 1 treated with sofosbuvir and ledipasvir.","volume":"66","author":"Younossi","year":"2018","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R7-20250514","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1097\/MPG.0b013e318185998f","article-title":"Impact of hepatitis C virus infection on children and their caregivers: quality of life, cognitive, and emotional outcomes.","volume":"48","author":"Rodrigue","year":"2009","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"R8-20250514","first-page":"1214","article-title":"Health-related quality of life (HRQOL) in children with chronic liver disease in North East Iran using PedsQL\u2122 4.0.","volume":"7","author":"Tehranian","year":"2015","journal-title":"Electron Physician"},{"key":"R9-20250514","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1111\/j.1440-1746.2007.04859.x","article-title":"Health-related quality of life in children with hepatitis C acquired in the first year of life.","volume":"23","author":"Nydegger","year":"2008","journal-title":"J Gastroenterol Hepatol"},{"key":"R10-20250514","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/jvh.12373","article-title":"Cognitive function and endogenous cytokine levels in children with chronic hepatitis C.","volume":"22","author":"Abu Faddan","year":"2015","journal-title":"J Viral Hepat"},{"key":"R11-20250514","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/hep.30840","article-title":"Pharmacokinetics, safety, and efficacy of glecaprevir\/pibrentasvir in adolescents with chronic hepatitis C virus: part 1 of the DORA study.","volume":"71","author":"Jonas","year":"2020","journal-title":"Hepatology"},{"key":"R12-20250514","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/liv.15744","article-title":"Health-related quality of life in patients aged 6-18 years with chronic hepatitis C treated with sofosbuvir\/velpatasvir.","volume":"44","author":"Pokorska-\u015apiewak","year":"2024","journal-title":"Liver Int"},{"key":"R13-20250514","doi-asserted-by":"crossref","first-page":"774","DOI":"10.5152\/tjg.2021.20594","article-title":"The assessment of the quality of life in children with chronic liver disease.","volume":"32","author":"Demiral","year":"2021","journal-title":"Turk J Gastroenterol"},{"key":"R14-20250514","doi-asserted-by":"crossref","first-page":"1871","DOI":"10.1111\/liv.15637","article-title":"Efficacy and safety of treatment with sofosbuvir\/velpatasvir in patients aged 6-18 years with chronic hepatitis C-results of the PANDAA-PED study.","volume":"43","author":"Pokorska-\u015apiewak","year":"2023","journal-title":"Liver Int"},{"key":"R15-20250514","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1007\/s11136-007-9240-2","article-title":"The KIDSCREEN-27 quality of life measure for children and adolescents: psychometric results from a cross-cultural survey in 13 European countries.","volume":"16","author":"Ravens-Sieberer","year":"2007","journal-title":"Qual Life Res"},{"key":"R17-20250514","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s11136-013-0428-3","article-title":"The European KIDSCREEN approach to measure quality of life and well-being in children: development, current application, and future advances.","volume":"23","author":"Ravens-Sieberer","year":"2014","journal-title":"Qual Life Res"},{"key":"R19-20250514","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1002\/jpn3.12045","article-title":"Sofosbuvir-velpatasvir in children 3-17 years old with hepatitis C virus infection.","volume":"78","author":"Jonas","year":"2024","journal-title":"J Pediatr Gastroenterol Nutr"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004675","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T21:13:56Z","timestamp":1747257236000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004675"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,20]]},"references-count":17,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004675","relation":{},"ISSN":["0891-3668","1532-0987"],"issn-type":[{"type":"print","value":"0891-3668"},{"type":"electronic","value":"1532-0987"}],"subject":[],"published":{"date-parts":[[2024,12,20]]}}}